Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
Peng Liubao (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China) Wan Xiaomin (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China) Tan Chongqing (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China) Jon Karnon (Department of Public Health, University of Adelaide, Adelaide, South Australia, Australia) Chen Gannong (Department of Mammary Gland and Thyroid Gland of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, PR China) Li Jianhe (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China) Cui Wei (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China) Luo Xia (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China) Cao Junhua (Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, PR China)
Abstract
Background: An oncology trial compared four cycles of doxorubicin/cyclophosphamide (AC) with four cycles of docetaxel/cyclophosphamide (TC) in operable breast cancer patients (71% were diagnosed with hormone receptor positive and 48% with node-negative breast cancer). The objective of this study was to estimate the lifetime cost effectiveness of AC versus TC, from a Chinese healthcare provider perspective, based on a clinical trial. Abstract: Methods: A lifetime cost-effectiveness analysis was performed using a Markov model. Events rates and utilities in the Markov model were derived from published papers. Data on cost of breast cancer care were obtained from the Second Xiangya Hospital of Central South University, Changsha, PR China. One-way sensitivity analysis and probabilistic sensitivity analysis were undertaken. Cost estimates were valued in Chinese yuan (Y), year 2008 values. All costs and outcomes were discounted at 3% per annum. Abstract: Results: Patients receiving TC gained 14.45 QALYs, 0.41 QALYs more than patients receiving AC. The lifetime costs of patients receiving TC were Y93 511, Y10 116 more than that of AC patients. The incremental cost-effectiveness ratios were Y26 742 per life-year gained (£2719.8 per year) and Y24 305 per QALY gained (£2471.9 per QALY). The most sensitive parameter in the model was the cost of primary cancer treatments in the TC arm. At a threshold willingness to pay of Y86 514 per QALY, the probability of TC being cost effective was 90%. Abstract: Conclusions: Our model suggests that TC may be considered cost effective from a Chinese healthcare provider perspective, according to the threshold defined by the WHO.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Publisher Info
Article provided by Wolters Kluwer Health | Adis in its journal PharmacoEconomics.
For technical questions regarding this item, or to correct its listing, contact: (Remco Bouckaert).
Related research
Keywords:
Find related papers by JEL classification: C - Mathematical and Quantitative Methods D - Microeconomics I - Health, Education, and Welfare Z - Other Special Topics I1 - Health, Education, and Welfare - - Health I19 - Health, Education, and Welfare - - Health - - - Other I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets